Portal de Periódicos da CAPES

PD62-12 6-NITRODOPAMINE IS RELEASED BY RAT ISOLATED VAS DEFERENS AND MODULATES ITS CONTRACTILITY

2021; Lippincott Williams & Wilkins; Volume: 206; Issue: Supplement 3 Linguagem: Inglês

10.1097/ju.0000000000002099.12

1527-3792

Luiz Ximenes, José Britto‐Júnior, Walter Silva-Filho, Felipe Fernandes Jacintho, Milton Cuppoloni, Adriano Fregonesi, Gilberto De Nucci,

Tissue Engineering and Regenerative Medicine

You have accessJournal of UrologySexual Function/Dysfunction: Basic Research & Pathophysiology (PD62)1 Sep 2021PD62-12 6-NITRODOPAMINE IS RELEASED BY RAT ISOLATED VAS DEFERENS AND MODULATES ITS CONTRACTILITY Luiz Eduardo Ximenes, José Britto-Júnior, Walter Silva-Filho, Felipe Jacintho, Milton Cuppoloni, Adriano Fregonesi, and Gilberto De Nucci Luiz Eduardo XimenesLuiz Eduardo Ximenes More articles by this author , José Britto-JúniorJosé Britto-Júnior More articles by this author , Walter Silva-FilhoWalter Silva-Filho More articles by this author , Felipe JacinthoFelipe Jacintho More articles by this author , Milton CuppoloniMilton Cuppoloni More articles by this author , Adriano FregonesiAdriano Fregonesi More articles by this author , and Gilberto De NucciGilberto De Nucci More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002099.12AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: 6-nitrodopamine (6-ND) is released by human umbilical cord vessels and acts as a dopamine D2-receptor antagonist in this tissue in vitro. Here it was investigated whether 6-ND is released by rat isolated vas deferens (RIVD) and its action on this tissue in vitro. METHODS: Segments of RIVD were suspended in 5 mL organ bath containing Krebs-Henseleit’s solution (KHS) containing ascorbic acid (3 mM) solution for 30 min and the quantification of 6-ND was performed by LC-MS-MS. For in vitro reactivity assay, RIVD epidydimal strips were suspended between two metal hooks in 10-mL organ baths containing KHS, continuously gassed with a mixture of 95%O2: 5% CO2 (pH 7.4) at 37°C. RESULTS: The detected basal release of 6-ND was 1.8±0.3 ng/mL (n=10) which was inhibited when the RIVD strips were pre-treated with the nitric oxide synthesis inhibitor L-NAME (0.8±0.2 ng/mL, n=10). 6-ND and noradrenaline caused concentration-dependent contractions of RIVD (pEC50 4.7±0.1 and 5.6±0.1, respectively; n=22). Desipramine (100 nM) inhibited 6-ND induced contractions (pEC50 3.7±0.1, n=5) but potentiated noradrenaline-induced contractions of RIVD (pEC50 6.6±0.1, n=5). Similar results were observed in human isolated vas deferens. Electric field stimulation (EFS) caused frequency dependent (4, 8 and 16 Hz) contractions which were inhibited by desipramine (100 nM, n=4; Figure A). This inhibitory effect of desipramine (100 nM) was not observed in the RIVD from animals chronically treated with L-NAME (n=4, Figure B). CONCLUSIONS: This is the first demonstration that 6-ND is released by vas deferens. The finding that L-NAME inhibits both the release of 6-ND and the contractions induced by EFS, indicates that 6-ND, and not noradrenaline, may be the mediator responsible for the EFS-induced contractions of RIVD. This hypothesis is further supported by the inhibition caused by desipramine in both 6-ND and EFS-induced contractions of RIVD. Source of Funding: CAPES Foundation and FAPESP © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e1077-e1077 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Luiz Eduardo Ximenes More articles by this author José Britto-Júnior More articles by this author Walter Silva-Filho More articles by this author Felipe Jacintho More articles by this author Milton Cuppoloni More articles by this author Adriano Fregonesi More articles by this author Gilberto De Nucci More articles by this author Expand All Advertisement Loading ...